Results 61 to 70 of about 11,777 (144)
COMPORTAMIENTO DEL INTERVALO QT CORREGIDO EN ARTRITIS TEMPRANA
Revista de la Facultad de Ciencias Médicas de Córdoba, 2016 Introducción: La dispersión del intervalo QT ha sido descripta en pacientes con artritis reumatoidea (AR) y puede ser un marcador útil de morbi-mortalidad cardiovascular.Objetivos: Conocer el comportamiento del intervalo QT corregido (iQTc) en ...Carla Andrea Gobbi, D Alessio, Paula Alba, P Asbert, E Albiero, D Salica, F Mártinez +6 moredoaj +1 more sourceDefining Bath Ankylosing Spondylitis Disease Activity Index Cut‐off Values for Disease Activity States in a Multinational European Cohort of Patients With Axial Spondyloarthritis
ACR Open Rheumatology, Volume 7, Issue 12, December 2025.Objective
The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is widely used for assessing disease activity in patients with axial spondyloarthritis (axSpA), particularly in settings where markers of inflammation are unavailable. As no consensus on BASDAI cut‐off values exists for disease activity states in axSpA, we aimed to develop and ...Stylianos Georgiadis, Lykke Midtbøll Ørnbjerg, Brigitte Michelsen, Tore K. Kvien, Mehrdad Shoae Kazemi, Jakub Závada, Karel Pavelka, Bente Glintborg, Anne Gitte Loft, Andreas Reich, Anne C. Regierer, Ana Maria Rodrigues, Maria José Santos, Jarno Rutanen, Laura Kuusalo, Adrian Ciurea, Michael J. Nissen, Bjorn Gudbjornsson, Ólafur Pálsson, Žiga Rotar, Katja Perdan Pirkmajer, Daniela Di Giuseppe, Mikkel Østergaard, Merete Lund Hetland +23 morewiley +1 more sourceEfficacy and Safety of ABBV‐154 for the Treatment of Active Rheumatoid Arthritis: A Phase 2b, Randomized, Placebo‐Controlled Trial
Arthritis &Rheumatology, Volume 77, Issue 12, Page 1673-1681, December 2025.Objective
Despite the availability of biologic and targeted synthetic disease‐modifying antirheumatic drugs (b/tsDMARDs) to treat rheumatoid arthritis (RA), many patients do not experience optimized disease control. Glucocorticoids are effective but have safety risks.Frank Buttgereit, Atul Singhal, Alan Kivitz, Edit Drescher, Yoshinori Taniguchi, Rosalía Martínez Pérez, Jaclyn Anderson, Ronilda D'Cunha, Weihan Zhao, Nicholas DeVogel, Julie Parmentier, Romy Christmann, Dilek Arikan, Howard Amital +13 morewiley +1 more sourceBioética en la práctica de reumatología
Revista Reumatología al Día, 2022 La actividad médica no es un acto cualquiera, está llena de grandes responsabilidades hacia un ser humano, se busca salvaguardar la salud y librarlo de la enfermedad, aliviando el dolor y mejorando su calidad de vida.
Salud es homologable a estar en el María del Carmen Ochoadoaj Editorial
Revista Argentina de Reumatología, 2013
La primera publicación oficial de la Sociedad Argentina de Reumatología fue el boletín de la Liga Argentina contra el Reumatismo, cuyo primer número apareció en octubre de 1938.Enrique Sorianodoaj +1 more sourceFirst‐line diagnostic tests to intercept primary heart involvement in systemic sclerosis: Clinical associations from the SPRING‐SIR registry
European Journal of Clinical Investigation, Volume 55, Issue 12, December 2025.Primary heart involvement (pHI) is a severe but often overlooked complication of systemic sclerosis (SSc), linked to heart failure, arrhythmias and mortality. In a study of 600 patients from the Italian SPRING‐SIR registry, 25% had ECG or echocardiographic signs of pHI at baseline, associated with older age, diffuse skin disease and intestinal symptoms.Antonio Tonutti, Francesca Motta, Rossella De Angelis, Edoardo Cipolletta, Clodoveo Ferri, Gianluigi Bajocchi, Silvia Bellando‐Randone, Cosimo Bruni, Martina Orlandi, Giovanni Zanframundo, Rosario Foti, Giovanna Cuomo, Alarico Ariani, Edoardo Rosato, Gemma Lepri, Francesco Girelli, Elisabetta Zanatta, Silvia Laura Bosello, Ilaria Cavazzana, Francesca Ingegnoli, Fabio Cacciapaglia, Giuseppe Murdaca, Giuseppina Abignano, Giorgio Pettiti, Alessandra Della Rossa, Maurizio Caminiti, Anna Maria Iuliano, Giovanni Ciano, Lorenzo Beretta, Gianluca Bagnato, Ennio Lubrano, Ilenia De Andres, Luca Idolazzi, Marta Saracco, Cecilia Agnes, Corrado Campochiaro, Marco Fornaro, Federica Lumetti, Amelia Spinella, Luca Magnani, Giacomo De Luca, Veronica Codullo, Elisa Visalli, Carlo Iandoli, Antonietta Gigante, Greta Pellegrino, Erika Pigatto, Maria Grazia Lazzaroni, Enrico De Lorenzis, Gianna Mennillo, Marco Di Battista, Giuseppa Pagano‐Mariano, Federica Furini, Licia Vultaggio, Simone Parisi, Clara Lisa Peroni, Gerolamo Bianchi, Enrico Fusaro, Gian Domenico Sebastiani, Marcello Govoni, Salvatore D'Angelo, Franco Cozzi, Franco Franceschini, Serena Guiducci, Lorenzo Dagna, Andrea Doria, Dilia Giuggioli, Valeria Riccieri, Carlo Salvarani, Florenzo Iannone, Marco Matucci‐Cerinic, Carlo Selmi, Maria De Santis, on behalf of SPRING‐SIR (Systemic Sclerosis PRogression INvestiGation group of the Italian Society for Rheumatology), Giorgio Amato, Alessia Benenati, Francesca Calabrese, Renato Carignola, Francesca Dall’Ara, Angelo De Cata, Claudio Di Vico, Marica Doveri, Nicoletta Romeo, Elena Generali, Gianluca Sambataro, Rossella Talotta, Alberto Lo Gullo, Carlo Scirè, Greta Carrara, Giampiero Landolfi, Davide Rozza, Anna Zanetti +91 morewiley +1 more sourceRenal vasculitis in Colombia
Revista Colombiana de Nefrología, 2015
A retrospective review of publications about primary vasculitis cases was performed from the Colombian medical literature, the clinical and pathological features are described.F Ramírez, W Rojas, D Jaramillo, C Ochoa, CA Toro, Paul Méndez-Patarroyo, P Coral, J Cantillo, G Ramírez, G Quintana, JF Restrepo, F Rondón, G Aroca, Antonio Iglesias Gamarra +13 moredoaj +1 more sourceImpact of Concomitant Methotrexate Use and Prior Biologic Disease‐Modifying Antirheumatic Drug Exposure on Tofacitinib Efficacy and Safety in Patients with Polyarticular Course Juvenile Idiopathic Arthritis: Post Hoc Analysis of a Phase 3 Randomized Withdrawal Trial
ACR Open Rheumatology, Volume 7, Issue 10, October 2025.Objective
We evaluate tofacitinib efficacy and safety in patients with juvenile idiopathic arthritis (JIA) stratified by concomitant methotrexate and prior biologic disease‐modifying antirheumatic drug (bDMARD) treatment. Methods
In this two part, double‐blind, randomized withdrawal Phase 3 trial (NCT02592434), patients (2–<18 years) with JIA received ...Nicolino Ruperto, Daniel J. Lovell, Olga Synoverska, Carlos Abud‐Mendoza, Alberto Spindler, Yulia Vyzhga, Iris Reyhan, Lyudmila Grebenkina, Irit Tirosh, Lisa Imundo, Peter Chiraseveenuprapund, Daniel J Kingsbury, Betul Sozeri, Sheetal S. Vora, Sampath Prahalad, Elena Zholobova, Kevin D. Roberts, Gosford Sawyerr, Andreas Blum, Andrea Shapiro, Annette Diehl, Abbas Ebrahim, Pascal Klaus, Alberto Martini, Hermine I. Brunner, for the Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG) +25 morewiley +1 more source